These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23387428)

  • 1. Novel OPA1 missense mutation in a family with optic atrophy and severe widespread neurological disorder.
    Liskova P; Ulmanova O; Tesina P; Melsova H; Diblik P; Hansikova H; Tesarova M; Votruba M
    Acta Ophthalmol; 2013 May; 91(3):e225-31. PubMed ID: 23387428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dominant optic atrophy, sensorineural hearing loss, ptosis, and ophthalmoplegia: a syndrome caused by a missense mutation in OPA1.
    Payne M; Yang Z; Katz BJ; Warner JE; Weight CJ; Zhao Y; Pearson ED; Treft RL; Hillman T; Kennedy RJ; Meire FM; Zhang K
    Am J Ophthalmol; 2004 Nov; 138(5):749-55. PubMed ID: 15531309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recessive optic atrophy, sensorimotor neuropathy and cataract associated with novel compound heterozygous mutations in OPA1.
    Lee J; Jung SC; Hong YB; Yoo JH; Koo H; Lee JH; Hong HD; Kim SB; Chung KW; Choi BO
    Mol Med Rep; 2016 Jul; 14(1):33-40. PubMed ID: 27150940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel OPA1 mutation causing variable age of onset autosomal dominant optic atrophy plus in an Australian family.
    Ahmad KE; Davis RL; Sue CM
    J Neurol; 2015 Oct; 262(10):2323-8. PubMed ID: 26194196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance.
    Hudson G; Amati-Bonneau P; Blakely EL; Stewart JD; He L; Schaefer AM; Griffiths PG; Ahlqvist K; Suomalainen A; Reynier P; McFarland R; Turnbull DM; Chinnery PF; Taylor RW
    Brain; 2008 Feb; 131(Pt 2):329-37. PubMed ID: 18065439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Not only dominant, not only optic atrophy: expanding the clinical spectrum associated with OPA1 mutations.
    Nasca A; Rizza T; Doimo M; Legati A; Ciolfi A; Diodato D; Calderan C; Carrara G; Lamantea E; Aiello C; Di Nottia M; Niceta M; Lamperti C; Ardissone A; Bianchi-Marzoli S; Iarossi G; Bertini E; Moroni I; Tartaglia M; Salviati L; Carrozzo R; Ghezzi D
    Orphanet J Rare Dis; 2017 May; 12(1):89. PubMed ID: 28494813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved locus-specific database for OPA1 mutations allows inclusion of advanced clinical data.
    Ferré M; Caignard A; Milea D; Leruez S; Cassereau J; Chevrollier A; Amati-Bonneau P; Verny C; Bonneau D; Procaccio V; Reynier P
    Hum Mutat; 2015 Jan; 36(1):20-5. PubMed ID: 25243597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of p.A684V missense mutation in the WFS1 gene as a frequent cause of autosomal dominant optic atrophy and hearing impairment.
    Rendtorff ND; Lodahl M; Boulahbel H; Johansen IR; Pandya A; Welch KO; Norris VW; Arnos KS; Bitner-Glindzicz M; Emery SB; Mets MB; Fagerheim T; Eriksson K; Hansen L; Bruhn H; Möller C; Lindholm S; Ensgaard S; Lesperance MM; Tranebjaerg L
    Am J Med Genet A; 2011 Jun; 155A(6):1298-313. PubMed ID: 21538838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-system neurological disease is common in patients with OPA1 mutations.
    Yu-Wai-Man P; Griffiths PG; Gorman GS; Lourenco CM; Wright AF; Auer-Grumbach M; Toscano A; Musumeci O; Valentino ML; Caporali L; Lamperti C; Tallaksen CM; Duffey P; Miller J; Whittaker RG; Baker MR; Jackson MJ; Clarke MP; Dhillon B; Czermin B; Stewart JD; Hudson G; Reynier P; Bonneau D; Marques W; Lenaers G; McFarland R; Taylor RW; Turnbull DM; Votruba M; Zeviani M; Carelli V; Bindoff LA; Horvath R; Amati-Bonneau P; Chinnery PF
    Brain; 2010 Mar; 133(Pt 3):771-86. PubMed ID: 20157015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel mutations in the OPA1 gene and associated clinical features in Japanese patients with optic atrophy.
    Nakamura M; Lin J; Ueno S; Asaoka R; Hirai T; Hotta Y; Miyake Y; Terasaki H
    Ophthalmology; 2006 Mar; 113(3):483-488.e1. PubMed ID: 16513463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pure and syndromic optic atrophy explained by deep intronic OPA1 mutations and an intralocus modifier.
    Bonifert T; Karle KN; Tonagel F; Batra M; Wilhelm C; Theurer Y; Schoenfeld C; Kluba T; Kamenisch Y; Carelli V; Wolf J; Gonzalez MA; Speziani F; Schüle R; Züchner S; Schöls L; Wissinger B; Synofzik M
    Brain; 2014 Aug; 137(Pt 8):2164-77. PubMed ID: 24970096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dominant optic atrophy, deafness, ptosis, ophthalmoplegia, dystaxia, and myopathy. A new syndrome.
    Treft RL; Sanborn GE; Carey J; Swartz M; Crisp D; Wester DC; Creel D
    Ophthalmology; 1984 Aug; 91(8):908-15. PubMed ID: 6493699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent OPA1 mutation and chromosome 3q deletion leading to Behr syndrome: a case report.
    Zeng T; Liao L; Guo Y; Liu X; Xiong X; Zhang Y; Cen S; Li H; Wei S
    BMC Pediatr; 2020 Sep; 20(1):420. PubMed ID: 32883255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biallelic Optic Atrophy 1 (
    Othman BA; Ong JE; Dumitrescu AV
    Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding the phenotype of PRPS1 syndromes in females: neuropathy, hearing loss and retinopathy.
    Almoguera B; He S; Corton M; Fernandez-San Jose P; Blanco-Kelly F; López-Molina MI; García-Sandoval B; Del Val J; Guo Y; Tian L; Liu X; Guan L; Torres RJ; Puig JG; Hakonarson H; Xu X; Keating B; Ayuso C
    Orphanet J Rare Dis; 2014 Dec; 9():190. PubMed ID: 25491489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes.
    Amati-Bonneau P; Valentino ML; Reynier P; Gallardo ME; Bornstein B; Boissière A; Campos Y; Rivera H; de la Aleja JG; Carroccia R; Iommarini L; Labauge P; Figarella-Branger D; Marcorelles P; Furby A; Beauvais K; Letournel F; Liguori R; La Morgia C; Montagna P; Liguori M; Zanna C; Rugolo M; Cossarizza A; Wissinger B; Verny C; Schwarzenbacher R; Martín MA; Arenas J; Ayuso C; Garesse R; Lenaers G; Bonneau D; Carelli V
    Brain; 2008 Feb; 131(Pt 2):338-51. PubMed ID: 18158317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optic atrophy and sensorineural hearing loss in a family caused by an R445H OPA1 mutation.
    Li C; Kosmorsky G; Zhang K; Katz BJ; Ge J; Traboulsi EI
    Am J Med Genet A; 2005 Oct; 138A(3):208-11. PubMed ID: 16158427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrafamilial "DOA-plus" phenotype variability related to different OMI/HTRA2 expression.
    Napolitano F; Terracciano C; Bruno G; Nesti C; Barillari MR; Barillari U; Santorelli FM; Melone MAB; Esposito T; Sampaolo S
    Am J Med Genet A; 2020 Jan; 182(1):176-182. PubMed ID: 31609081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomics combined with a protein informatics platform to assess a novel pathogenic variant c.1024 A>G (p.K342E) in OPA1 in a patient with autosomal dominant optic atrophy.
    Ahuja AS; Selvam P; Vadlamudi C; Chopra H; Richter JE; Macklin SK; Samreen A; Helmi H; Mohammaad AN; Hines S; Davila MC; Atwal PS; Caulfield TR
    Ophthalmic Genet; 2020 Dec; 41(6):563-569. PubMed ID: 32940104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The G401D mutation of OPA1 causes autosomal dominant optic atrophy and hearing loss in a Chinese family.
    Ke T; Nie SW; Yang QB; Liu JP; Zhou LN; Ren X; Liu JY; Wang Q; Liu MG
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Oct; 23(5):481-5. PubMed ID: 17029191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.